We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eterna Therapeutics Inc | NASDAQ:ERNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.08 | 1.90 | 2.11 | 18 | 13:53:44 |
Delaware | | | 31-1103425 |
(State or other jurisdiction of incorporation or organization) | | | (I.R.S. Employer Identification No.) |
| | ||
1035 Cambridge Street, Suite 18A Cambridge, MA 02141 | | | 02141 |
(Address of Principal Executive Offices) | | | (Zip Code) |
Large accelerated filer | | | ☐ | | | Accelerated filer | | | ☐ |
Non-accelerated filer | | | ☒ | | | Smaller reporting company | | | ☒ |
| | | | Emerging growth company | | | ☐ |
Item 3. | Incorporation of Documents by Reference. |
Item 4. | Description of Securities. |
Item 5. | Interests of Named Experts and Counsel. |
Item 6. | Indemnification of Directors and Officers. |
Item 7. | Exemption from Registration Claimed. |
Item 8. | Exhibits. |
Exhibit Number | | | Exhibit Description | | | Filed Herewith | | | Incorporated by Reference herein from Form or Schedule | | | Filing Date | | | SEC File/ Reg. Number |
| | Composite Restated Certificate of Incorporation of the Registrant. | | | | | Form 10-K (Exhibit 3.1) | | | 03/20/2023 | | | 001-11460 | ||
| | Certificate of Validation of the Registrant. | | | | | Form 8-K (Exhibit 3.1) | | | 09/13/2021 | | | 001-11460 | ||
| | Second Amended and Restated Bylaws of the Registrant. | | | | | Form 8-K (Exhibit 3.2) | | | 10/11/2022 | | | 001-11460 | ||
| | Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. | | | X | | | | | | | ||||
| | Eterna Therapeutics Inc. Restated 2020 Stock Incentive Plan. | | | | | Form 8-K (Exhibit 99.1) | | | 09/13/2021 | | | 001-11460 | ||
| | Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in opinion of counsel filed Exhibit 5.1). | | | X | | | | | | | ||||
| | Consent of Grant Thornton LLP, independent registered public accounting firm. | | | X | | | | | | | ||||
| | Consent of Marcum LLP, independent registered public accounting firm. | | | X | | | | | | | ||||
| | Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement). | | | X | | | | | | | ||||
| | Form of Stock Option Inducement Award. | | | X | | | | | | | ||||
| | Filing Fee Table. | | | X | | | | | | |
| | ETERNA THERAPEUTICS INC. | ||||
| | | | |||
| | By: | | | /s/ Sanjeev Luther | |
| | Sanjeev Luther | ||||
| | President and Chief Executive Officer |
Name | | | Title | | | Date |
| | | | |||
/s/ Sanjeev Luther | | | President and Chief Executive Officer (Principal Executive Officer) | | | January 16, 2024 |
Sanjeev Luther | | |||||
| | | | |||
/s/ Sandra Gurrola | | | Senior Vice President of Finance (Principal Financial and Accounting Officer) | | | January 16, 2024 |
Sandra Gurrola | | |||||
| | | | |||
/s/ James Bristol | | | Director | | | January 16, 2024 |
James Bristol | | |||||
| | | | |||
/s/ William Wexler | | | Director | | | January 16, 2024 |
William Wexler | | |||||
| | | | |||
/s/ Dorothy J. Clarke | | | Director | | | January 16, 2024 |
Dorothy J. Clarke | |
919 Third Avenue,
New York, NY 10022
212 935 3000
mintz.com
|
Very truly yours,
|
/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
|
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
|
Participant Name:
|
|
Sanjeev Luther
|
Grant ID:
|
|
48697
|
Grant Date:
|
|
January 1, 2024
|
Exercise Price per Share:
|
|
$1.80
|
Number of Shares:
|
|
1,685,218
|
Type of Option:
|
|
Nonqualified Stock Option
|
Expiration Date:
|
|
January 1, 2034
|
Vesting Commencement Date:
|
|
January 1, 2024
|
Vesting Schedule:
|
|
The Shares shall vest in an initial installment of 25% on the one-year anniversary of the Grant Date, and the remaining Shares shall vest in 36 substantially equal
monthly installments thereafter.
Upon the occurrence of a Change in Control (as defined in the Plan) and ending
on the first anniversary of the occurrence of the Change in Control (the “Change in Control Protection Period”), if the Company shall terminate Participant’s employment
other than for Disability or Cause (as defined in Participant’s Employment Agreement), or if Participant shall terminate employment for Good Reason (as defined in Participant’s Employment Agreement), then any outstanding and unvested
portion of this Option shall become immediately vested and exercisable upon such date of termination.
|
1.
|
This Option is governed by all the terms and conditions of the Plan applicable to this Option, whether or not such terms and conditions are stated in the Award Agreement. This Option is
governed by the terms and conditions of this Award Agreement. In the event of a conflict between the terms of the Plan and this Award Agreement, the terms of the Plan will prevail.
|
2.
|
Participant has received a copy of the Plan, this Award Agreement, the Plan prospectus (if required under applicable law), and the Company’s insider trading policy, and represents that
he or she has read these documents and is familiar with their terms. Participant further agrees to accept as binding, conclusive, and final all decisions and interpretations of the Committee regarding any questions relating to this Option
and the Plan.
|
3.
|
Vesting of this Option is subject to Participant’s continued employment as an employee, which is for an unspecified duration and may be terminated at any time, with or without Cause,
and nothing in this Award Agreement or the Plan changes the nature of that relationship.
|
4.
|
The Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendations regarding participation in the Plan. Participant should consult with his or her own personal tax, legal, and financial advisors regarding participation in the Plan before taking any action related to the Plan.
|
5.
|
Participant consents to electronic delivery and participation as set forth in this Award Agreement.
|
6.
|
If Participant does not accept or decline this Option within 60 days of the Grant Date or by such other date
that may be communicated to Participant by the Company, the Company will accept this Option on Participant’s behalf and Participant will be deemed to have accepted the terms and conditions of this Option set forth in the Plan and this
Award Agreement. If Participant wishes to decline this Option, Participant should promptly notify Sandra Gurrola at sandra.gurrola@eternatx.com . If Participant declines this Option, this Option will be cancelled and no benefits from
this Option nor any compensation or benefits in lieu of this Option will be provided to Participant.
|
Eterna Therapeutics Inc.
|
|
Participant
|
||
By:
|
Signature:
|
|||
Title:
|
Date:
|
1.
|
Grant of Option. Capitalized terms used in the Award Agreement but not defined in the Award
Agreement will have the same meanings specified in the Plan. The Company and Participant understand and agree that the Option shall be granted in compliance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to the Participant
entering into employment with the Company. Participant has been granted an Option to purchase up to the number of Shares set forth in the Notice at the Exercise Price set forth in the Notice.
|
2.
|
Exercise of Option. This Option is exercisable during its term in accordance with the Vesting
Schedule contained in the Notice and the applicable provisions of the Plan and the Award Agreement. Participant may exercise the vested portion of this Option only by following the option exercise procedures established by the Committee
and payment of the aggregate Exercise Price for the Shares to be purchased, together with any applicable taxes that the Company is required by any law or regulation of any governmental authority, whether federal, state or local, domestic
or foreign (“Taxes”), to withhold in connection with the exercise of the Option.
|
3.
|
Method of Payment. Participant may always pay the Exercise Price by personal check (or readily
available funds), wire transfer, or cashier’s check. The Participant may also pay the Exercise Price by means of a “cashless exercise sale and remittance procedure” (as described in the Plan). The Committee may also allow any other method
of payment permitted by Section 6(h) of the Plan in its discretion at the time of exercise, and any restrictions deemed necessary or appropriate to facilitate compliance with applicable law or administration of the Plan (including to
avoid the recognition of additional compensation expenses for financial reporting purposes).
|
4.
|
Option Term.
|
a.
|
Maximum Term. This Option will in all events expire at the close of business at Company
headquarters on the Expiration Date specified in the Notice, unless it terminates earlier in connection with the termination of Participant’s employment (as provided below) or a Change in Control (as provided in the Plan).
|
b.
|
Post-Termination Exercise Period. If Participant’s employment terminates prior to the
Expiration Date of this Option other than for Cause, the unvested portion of this Option will automatically expire on Participant’s date of termination, and the vested portion of this Option will remain outstanding and exercisable for the
following periods, unless otherwise determined by the Committee and in no event after the Expiration Date of this Option:
|
|
i.
|
ninety (90) days following a termination for any reason other than Cause, Disability, or death;
|
|
ii.
|
twelve (12) months following a termination due to Disability;
|
|
iii.
|
twelve (12) months following the date of Participant’s death, if Participant dies while in employment, or during the period provided in clause (ii) above; and
|
|
iv.
|
upon the occurrence of a Change in Control during the Change in Control Protection Period, if the Company shall terminate Participant’s employment other than for Disability or
Cause, or if Participant shall terminate employment for Good Reason, then all outstanding and vested shares under this Option, including any accelerated vesting of shares under this Option pursuant to the vesting schedule above, will
remain exercisable for a period of twelve (12) months following the date of termination.
|
c.
|
Termination for Cause. If Participant’s employment is terminated for Cause, this Option will
terminate and be forfeited immediately upon such Participant’s termination of employment, and Participant will be prohibited from exercising any portion (including any vested portion) of this Option on or after the date of such
termination. If Participant’s employment is suspended pending an investigation of whether Participant’s employment will be terminated for Cause, all of Participant’s rights under this Option, including the right to exercise the Option,
shall be suspended during the investigation period.
|
d.
|
Determination of Termination Date. For purposes of this Option, Participant’s employment will
be considered terminated as of the date Participant is no longer actively providing services to the Company Group (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws
in the jurisdiction where Participant is employed or the terms of Participant’s employment agreement, if any). The Committee shall have the exclusive discretion to determine when Participant is no longer actively providing services for
purposes of this Option (including whether Participant may still be considered to be providing services while on a leave of absence).
|
e.
|
No Notice of Option Expiration. Participant is responsible for keeping track of the Expiration
Date and the post-termination exercise periods following Participant’s termination of employment for any reason. The Company is not obligated to provide further notice of such periods. In no event will this Option be exercised later than
the Expiration Date set forth in the Notice.
|
5.
|
Non-Transferability of Option. This Option may not be transferred in any manner other than by
will or by the laws of descent or distribution or court order and may be exercised during the lifetime of Participant only by Participant. The terms of the Plan and this Award Agreement will be binding upon the executors, administrators,
heirs, successors, and assigns of Participant.
|
6.
|
Taxes.
|
a.
|
Responsibility for Taxes. By
accepting this Option, Participant acknowledges that, regardless of any action taken by the Company or, if different, any member of the Company Group that employs Participant (the “Employer”), the ultimate liability for all Taxes is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company or the Employer. Participant further
acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Taxes in connection with any aspect of this Option, including, but not limited to, the grant, vesting, or
exercise of this Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of this
Option to reduce or eliminate Participant’s liability for Taxes or achieve any particular tax result. Further, if Participant is subject to Taxes in more than one jurisdiction, as applicable, Participant acknowledges that the Company
and/or the Employer may be required to withhold or account for Taxes in more than one jurisdiction. Participant agrees to pay to the Company or the Employer any amount of Taxes that the Company or the Employer may be required to
withhold or account for as a result of Participant’s participation in the Plan that cannot be satisfied by the means described in this Section. The Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares,
if Participant fails to comply with Participant’s obligations in connection with the Taxes.
|
b.
|
Withholding. Prior to the relevant taxable or tax withholding event, as applicable,
Participant agrees to make adequate arrangements satisfactory to the Company and/or the Employer to satisfy all Taxes. In this regard, Participant authorizes the Company or the Employer, or their respective agents, at their discretion, to
satisfy the obligations with regard to all Taxes by one or a combination of the following:
|
|
i.
|
withholding from Participant’s wages or other cash compensation paid to Participant by the Company and/or the Employer or any member of the Company Group;
|
|
ii.
|
withholding from proceeds of the sale of Shares acquired at exercise of this Option either through a voluntary sale or through a mandatory sale arranged by the Company
(on Participant’s behalf pursuant to this authorization and without further consent);
|
|
iii.
|
withholding Shares to be issued upon exercise of this Option, provided the Company only withholds a number of Shares necessary to satisfy no more than the withholding
amounts determined based on the maximum permitted statutory rate applicable in Participant’s jurisdiction;
|
|
iv.
|
Participant’s payment of a cash amount (including by check representing readily available funds or a wire transfer); or
|
|
v.
|
any other arrangement approved by the Committee and permitted under applicable law.
|
7.
|
Nature of Grant. In accepting this Option, Participant acknowledges, understands and agrees
that: (a) the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan; (b) the grant of this Option is
voluntary and occasional and does not create any contractual or other right to receive future grants, or benefits in lieu of grants, even if grants have been made in the past; (c) all decisions with respect to future grants, if any, will
be at the sole discretion of the Company; (d) Participant is voluntarily participating in the Plan; (e) this Option and the Shares allocated to this Option are not intended to replace any pension rights or compensation and are outside the
scope of Participant’s employment contract, if any; (f) this Option and the Shares allocated to this Option, and the income and value of same, are not part of normal or expected compensation for any purpose, including, without limitation,
calculating any severance, resignation, termination, redundancy, dismissal, end-of- service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; (g) unless otherwise provided in the Plan
or by the Company in its discretion, this Option and the benefits evidenced by this Award Agreement do not create any entitlement to have this Option or any such benefits transferred to, or assumed by, another company nor to be exchanged,
cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and (h) neither the Company nor any member of the Company Group shall be liable for any foreign exchange rate fluctuation between
Participant’s local currency and the United States Dollar or the selection by the Company or any member of the Company Group in its sole discretion of an applicable foreign exchange rate that may affect the value of this Option (or the
calculation of income or Taxes thereunder) or of any amounts due to Participant pursuant to the settlement of this Option or the subsequent sale of the Shares allocated to this Option.
|
8.
|
Code Section 409A. It is intended that the terms of this Option will not result in the
imposition of any tax liability pursuant to Section 409A of the Code, and this Award Agreement shall be construed and interpreted consistent with that intent. Notwithstanding the foregoing, no member of the Company Group shall be liable
for any costs incurred by Participant under Section 409A of the Code and similar state laws.
|
9.
|
Data Privacy. Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant’s personal data as described in this Award Agreement and any other grant
materials by and among the Company and the members of the Company Group for the purpose of implementing, administering and managing Participant’s participation in the Plan. Participant understands that the Company and the members of the
Company Group may hold certain personal information about Participant, including, but not limited to, Participant’s name, home address and telephone number, date of birth, social insurance number or other identification number, salary,
nationality, job title, any Shares or directorships held in the Company, details of all grants, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant’s favor (“Data”), for
the purpose of implementing, administering and managing the Plan. Participant understands that Data will be transferred to such stock plan service provider as may be selected by the Company, presently or in the future, which may be
assisting the Company with the implementation, administration and management of the Plan. Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipient’s country (e.g.,
the United States) may have different data privacy laws and protections than Participant’s country. Participant authorizes the Company, the stock plan service provider as may be selected by the Company, and any other possible recipients
which may assist the Company, presently or in the future, with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing,
administering and managing Participant’s participation in the Plan. Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis. If Participant does not consent, or if Participant later
seeks to revoke his or her consent, or instructs the Company to cease the processing of the Data, his or her employment or service will not be adversely affected; the only adverse consequence of refusing or withdrawing Participant’s
consent or instructing the Company to cease processing, is that the Company would not be able to grant Participant the Option or any other equity awards or administer or maintain such awards. Therefore, Participant understands that
refusing or withdrawing his or her consent may affect Participant’s ability to participate in the Plan. For more information on the consequences of Participant’s refusal to consent or withdrawal of consent, Participant understands that
he or she may contact his or her local human resources representative.
|
10.
|
Governing Law and Venue. This Award Agreement shall be governed by and
construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. For purposes of litigating any dispute that arises directly or indirectly from the relationship of
the parties evidenced by this grant or this Award Agreement, the parties hereby submit to the exclusive jurisdiction of the State of Delaware and agree that such litigation shall be conducted only in the courts of the State of Delaware,
or the federal courts for the United States for the District of Delaware, and no other courts, where this grant is made and/or to be performed.
|
11.
|
Addendum and Sub-Plans. Notwithstanding any provisions in this Award
Agreement, this Option shall be subject to any special terms and conditions set forth in any Addendum to this Award Agreement for Participant’s country. Moreover, if Participant relocates to one of the countries included in the Addendum
(if any), the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.
The Addendum (if any) constitutes part of this Award Agreement. Further, the Plan shall be deemed to include any special terms and conditions set forth in any applicable sub-plan for Participant’s country, and, if Participant relocates to
a country for which the Company has established a sub-plan, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary
or advisable for legal or administrative reasons.
|
12.
|
Entire Agreement; Enforcement of Rights; Amendment. This Award Agreement,
together with the Plan, sets forth the entire agreement and understanding of the parties relating to the subject matter herein and supersedes all prior or contemporaneous discussions, agreements, commitments, negotiations and arrangements
between them. Except as contemplated by the Plan, no modification of or amendment to this Award Agreement, nor any waiver of any rights under this Award Agreement, shall be effective unless in writing signed by the parties to this Award
Agreement to the extent it would alter or impair rights or obligations under the Option. The failure by either party to enforce any rights under this Award Agreement shall not be construed as a waiver of any rights of such party.
Notwithstanding anything to the contrary in the Plan or this Award Agreement, the Company reserves the right to revise this Award Agreement as it deems necessary or advisable, in its sole discretion and without the consent of Participant,
to comply with Section 409A of the Code or to otherwise avoid imposition of any additional tax or income recognition or costs under Section 409A of the Code in connection with this Option.
|
13.
|
Severability. If one or more provisions of this Award Agreement are held to
be unenforceable under applicable laws, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision
shall be excluded from this Award Agreement, (b) the balance of this Award Agreement shall be interpreted as if such provision were so excluded, and (c) the balance of this Award Agreement shall be enforceable in accordance with its
terms.
|
14.
|
Language. If Participant has received this Award Agreement, the Plan or any other document
related to this Option and/or the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.
|
15.
|
Imposition of Other Requirements. The Company reserves the right to impose
other requirements on Participant’s participation in the Plan, on this Option and on any Shares purchased upon exercise of this Option, to the extent the Company determines it is necessary or advisable for legal or administrative reasons,
and to require Participant to accept any additional agreements or undertakings that may be necessary to accomplish the foregoing.
|
16.
|
Notices. Any notice, demand or request required or permitted to be given
under this Award Agreement shall be in writing and shall be deemed sufficient when delivered personally or by overnight courier or sent by email or fax, or forty-eight (48) hours after being deposited in the U.S. mail or a comparable
foreign mail service, as certified or registered mail with postage or shipping charges prepaid, addressed to the party to be notified at such party’s address as set forth on the signature page, as subsequently modified by written notice,
or if no address is specified on the signature page, at the most recent address, email or fax number set forth in the Company’s books and records.
|
17.
|
Counterparts. This Award Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. Facsimile, email or other electronic execution and delivery of this Award Agreement (including but not limited to execution
by electronic signature or click-through electronic acceptance) shall constitute valid and binding execution and delivery for all purposes and shall be deemed to be, and have the effect of, an original signature.
|
18.
|
Successors and Assigns. The rights and benefits of this Award Agreement shall inure to the benefit of,
and be enforceable by the Company’s successors and assigns.
|
19.
|
Consent to Electronic Delivery and Participation. By accepting this Option,
Participant agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company, and consents to the electronic delivery of the Award Agreement,
the Plan, account statements, Plan prospectuses (if any), and all other documents, communications, or information related to this Option and current or future participation in the Plan. Electronic delivery may include the delivery of a
link to the Company intranet or the internet site of a third party involved in administering the Plan, the delivery of the document via e-mail or such other delivery determined at the Company’s discretion. Participant acknowledges that
Participant may receive from the Company a paper copy of any documents delivered electronically at no cost if Participant contacts the Company by telephone, through a postal service, or electronic mail to the Chief Financial Officer.
|
|
|
|
|
|
|
|
|
|||||||
Security Type
|
Security
Class
Title
|
Fee
Calculation
Rule
|
Amount
Registered(1)
|
Proposed
Maximum
Offering
Price Per
Unit(2)
|
Maximum
Aggregate Offering
Price |
Fee
Rate
|
Amount of
Registration Fee |
|||||||
|
|
|
|
|
|
|
|
|||||||
Equity
|
|
Common Stock, par value $0.001 per share
|
|
457(c)
and
457(h)
|
|
2,512,087
|
|
$1.915
|
|
$4,810,646.61
|
|
$0.00014760
|
|
$710.05
|
|
|
|
|
|
||||||||||
Total Offering Amount
|
|
|
$4,810,646.61
|
|
|
$710.05
|
||||||||
|
|
|
|
|
||||||||||
Total Fees Previously Paid
|
|
|
|
|
—
|
|||||||||
|
|
|
|
|
||||||||||
Total Fee Offsets
|
|
|
|
|
—
|
|||||||||
|
|
|
|
|
||||||||||
Net Fee Due
|
|
|
|
|
|
|
|
$710.05
|
(1)
|
The number of shares of common stock, par value $0.005 per share (“Common Stock”), of Eterna Therapeutics Inc. (the “Registrant”) stated above consists of (i) 826,869 additional
shares of Common Stock available for issuance under the Registrant’s Restated 2020 Stock Incentive Plan, as amended (the “2020 Plan”) and (ii) 1,685,218 shares of Common Stock issuable pursuant to a stock option award granted to Dr.
Sanjeev Luther, the President and Chief Executive Officer of the Registrant, to induce such individual to accept employment with the Registrant in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Award”). The maximum number of shares which may be sold upon the exercise of options or issuance of stock-based awards granted under the 2020 Plan are subject to adjustment in accordance with certain anti-dilution and other provisions of
the 2020 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement covers, in addition to the number of shares stated above, an indeterminate number of shares
which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions.
|
(2)
|
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate
offering price for shares reserved for future grant or issuance under the 2020 Plan and the Inducement Award are based on the average of the high and the low price of Registrant’s Common Stock as reported on The Nasdaq Global Select Market as
of a date (January 10, 2024) within five business days prior to filing this Registration Statement.
|
1 Year Eterna Therapeutics Chart |
1 Month Eterna Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions